高度肺神经内分泌癌的亚型是否会影响治疗选择?
Helmut Popper1, Luka Brcic1, Sylvia Eidenhammer1
1D&F Institute of Pathology, Medical University of Graz, Graz, Austria.
Translational lung cancer research
|January 11, 2024
概括
这项研究基于特定的蛋白质表达,确定了小细胞肺癌 (SCLC) 和大细胞神经内分泌癌 (LCNEC) 的不同亚型. 这些发现可能会指导针对这些侵袭性肺癌的向疗法和免疫疗法.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 分子病理学分子病理学
背景情况:
- 小细胞肺癌 (SCLC) 和大细胞神经内分泌癌 (LCNEC) 是具有有限治疗进展的侵袭性胸部恶性瘤.
- 目前对SCLC的治疗策略基本没有变化,而LCNEC治疗仍在争论中,在SCLC类型和非小细胞肺癌 (NSCLC) 类型治疗方法之间存在差异.
- 最近的研究已经确定了SCLC中的潜在分子亚型,包括ASCL1,NeuroD1和POU2F3,还提出了YAP1和炎症亚型.
研究的目的:
- 通过免疫组织化学研究,研究SCLC和LCNEC中特定亚型 (ASCL1,NeuroD1,POU2F3) 的表达.
- 探索免疫组织化学标志物的潜力,以识别可能受益于向治疗策略的患者.
- 在独立的活检集中验证亚型表达模式.
主要方法:
- 对SCLC和LCNEC组织样本进行免疫组织化学分析,以确定各种分子标记物的表达.
- 对亚型特定标记物 (ASCL1,NeuroD1,POU2F3,YAP1,TAZ,ATOH,HES1) 和潜在的治疗标 (N-MYC,AURKA,FGFR2) 的研究.
- 评估细胞瘤细胞中编程细胞死亡配体1 (PD-L1) 的表达.
主要成果:
- 在SCLC和LCNEC中,ASCL1,NeuroD1和POU2F3亚型的百分比不同,在所有活检样本中一致.
- 大多数情况下,极光激酶A (AURKA) 的表达高,而N-MYC是主导的MYC蛋白;既不与特定亚型相关.
- 编程细胞死亡配体1 (PD-L1) 主要表达在树皮细胞上,纤维细胞生长因子受体2 (FGFR2) 表达有限.
结论:
- SCLC和LCNEC可以分为ASCL1,NeuroD1和POU2F3阳性亚型.
- 在SCLC和LCNEC中,AURKA和FGFR2代表了潜在的治疗点,需要根据标记物的表达选择患者.
- 在树突细胞中的PD-L1染色可能会为结合化疗和免疫治疗的决定提供信息.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.8K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166